Post-Marketing Safety Study on Olumiant (Baricitinib) Use Among Moderate to Severe Active Rheumatoid Arthritis Patients in China

Study identification

• EU PAS number:
  EUPAS34213
• Study ID:
  34214
• Official title and acronym:
  Post-Marketing Safety Study on Olumiant (Baricitinib) Use Among Moderate to Severe Active Rheumatoid Arthritis Patients in China
• DARWIN EU® study:
  No
• Study countries:
  China
• Study status:
  Finalised

Research institutions and networks

Institutions

Peking Union Medical College Hospital

Multiple centres: 31 centres are involved in the study

Study timelines

Date when funding contract was signed

Planned: 01/05/2020

Actual: 01/05/2020

Study start date

Planned: 31/08/2020

Actual: 31/08/2020

Data analysis start date

Actual: 25/11/2022

Date of final study report

Planned: 30/12/2022

Actual: 09/05/2023

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Eli lilly

Regulatory

• Was the study required by a regulatory body?:
  Yes
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable